Source: International Congress 2015 – New data on established treatments for asthma and COPD
Disease area: Airway diseases, Respiratory infections

Abstract

Contrary to GOLD recommendations, patients at low risk of exacerbation and moderate airflow limitation are frequently prescribed inhaled corticosteroids.¹Recent data from INSTEAD showed that patients with moderate COPD and no exacerbations in the previous year can be switched from SFC 50/500µg BID to indacaterol 150µg with no efficacy decrease.² Exploratory symptom efficacy data are presented here.Methods were published previously.² Patients recorded morning/evening daily respiratory symptoms, cough, wheezing, sputum volume and colour, breathlessness, sore throat, cold and fever. This analysis was a prespecified exploratory objective.The percentage of nights with no night-time awakenings, days with no daytime symptoms, and days able to perform usual daily activities were calculated over 12 and 26 wks treatment, as were mean individual diary symptom scores.There were no statistically significant differences between indacaterol and SFC for any variable, illustrated in Table 1.Patients at low risk of exacerbation can be switched from SFC to indacaterol with no deterioration in symptoms or symptoms scores.1 Vestbo J et al Respir Med 2014;108:729-362 Rossi A et al ERJ 2014;44:1548-56

Daily score	Week 12		Week 26
	LS mean (CI)	p value	LS mean (CI)	p value
Cough	0.04 ( -0.07, 0.16)	0.458	0.03 ( -0.09, 0.16)	0.586
Wheezing	0.00 ( -0.11, 0.11)	0.954	-0.02 ( -0.14, 0.09)	0.672
Production of sputum	0.02 ( -0.11, 0.14)	0.806	-0.01 ( -0.13, 0.12)	0.934
Colour of sputum	0.06 ( -0.04, 0.16)	0.273	0.04 ( -0.07, 0.14)	0.511
Breathlessness	0.00 ( -0.12, 0.13)	0.961	0.02 ( -0.12, 0.15)	0.825
Sore throat	-0.03 (-0.10, 0.04)	0.428	-0.04 ( -0.11, 0.03)	0.232
Cold	0.00 ( -0.12, 0.12)	0.999	-0.03 ( -0.16, 0.10)	0.678
Fever	0.00 ( -0.02, 0.03)	0.827	0.01 ( -0.02, 0.03)	0.618

 

Rating:

Share or cite this content

Citations should be made in the following way:
Andrea Rossi (Verona, Italy), Andrea Rossi, Thys Van der Molen, Ricardo Del Olmo, Alberto Papi, Luis Wehbe, Matthew Quinn, Chengxing Lu, David Young, Ray Cameron, Pablo Altman. INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results. Eur Respir J 2015; 46: Suppl. 59, 1023

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD Source: Eur Respir J 2014; 44: 1548-1556 Year: 2014 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Roflumilast for stable COPD: Meta-analysis of randomized controlled trials Source: International Congress 2014 – Clinical presentations Year: 2014 A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016 Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002 A double-blind, double-dummy, randomized study of beclomethasone/formoterol versus fluticasone/salmeterol in treatment of moderate to severe asthma in Taiwan Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015